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matory state. We have previously shown that A20 expression 
positively correlates with lung function (FEV 1 %) in CF. De-
spite improvement in survival rates in recent years, advance-
ments in available therapies have been incremental. We 
demonstrate that the experimental use of naturally occur-
ring plant diterpenes such as gibberellin on lipopolysaccha-
ride-stimulated cell lines reduces IL-8 release in an A20-de-
pendent manner. We discuss how the use of a novel bio-in-
formatics gene expression connectivity-mapping technique 
to identify small molecule compounds that similarly mimic 
the action of A20 may lead to the development of new ther-
apeutic approaches capable of reducing chronic airway in-
flammation in CF.  © 2015 S. Karger AG, Basel 
 Introduction 
 Cystic fibrosis (CF) is a chronic inflammatory multi-
organ disease, caused by mutations in the CF transmem-
brane conductance regulator (CFTR) gene, which is ex-
pressed on many epithelial surfaces, and various cell types 
including myeloid and red blood cells  [1, 2] . It is the most 
common lethal genetic disease in Caucasian populations 
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 Abstract 
 Cystic fibrosis (CF) is a lifelong, inflammatory multi-organ 
disease and the most common lethal, genetic condition in 
Caucasian populations, with a median survival rate of 41.5 
years. Pulmonary disease, characterized by infective exacer-
bations, bronchiectasis and increasing airway insufficiency is 
the most serious manifestation of this disease process, cur-
rently responsible for over 80% of CF deaths. Chronic dys-
regulation of the innate immune and host inflammatory re-
sponse has been proposed as a mechanism central to this 
genetic condition, primarily driven by the nuclear factor κB 
(NF-κB) pathway. Chronic activation of this transcription fac-
tor complex leads to the production of pro-inflammatory cy-
tokines and mediators such as IL-6, IL-8 and TNF-α. A20 has 
been described as a central and inducible negative regulator 
of NF-κB. This intracellular molecule negatively regulates NF-
κB-driven pro-inflammatory signalling upon toll-like recep-
tor activation at the level of TRAF6 activation. Silencing of 
A20 increases cellular levels of p65 and induces a pro-inflam-
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( ∼ 1 in 3,000 live births). Inheritance is autosomal reces-
sive in nature, and, within Caucasian populations, the 
carrier rate can be as high as 1: 25  [3] .
 The incidence of CF in the United Arab Emirates and 
Saudi Arabia is 1: 16,000 and 1: 4,000, respectively  [4,
5] , while in Caucasian populations it is approximately
1: 2,500, with comparable carrier rates throughout North 
America, the UK and Europe  [6] . Eight thousand people 
are currently living with CF in the UK, with a median pre-
dicted survival of 41.5 years  [7] . Current UK models pre-
dict that a child born today can typically expect to live to 
be 50 years of age or more  [7] , but advances in available 
therapies to date have been incremental. 
 More than 1,800 mutations have been identified in the 
CFTR gene, but the functional significance of only a small 
number is known  [8–10] . The most common mutation, 
F508del, accounts for over two thirds of all mutations in 
northern Caucasian populations. This mutation is caused 
by a phenylalanine deletion at position 508 on chromo-
some 7. Despite the vast number of identified CFTR mu-
tations, no other mutation accounts for more than 5% of 
CF cases in any one population  [8–10] .
 The mutations in the CFTR gene most commonly af-
fect the respiratory, gastrointestinal and reproductive 
systems. Up to 15% of CF babies are born with a meco-
nium ileus, which is a sensitive differential sign of the dis-
ease at birth  [11] . Whilst pancreatic insufficiency, biliary 
cirrhosis, CF-related diabetes mellitus and infertility are 
serious comanifestations of the disease  [12] , pulmonary 
insufficiency hallmarked by bronchiectasis, hypercarbia 
and chronic airway infection remains responsible for at 
least 80% of CF-related deaths  [13] . 
 In the lungs, ion imbalances caused by a loss of inhibi-
tion of the epithelial sodium channels as a result of CFTR 
dysfunction lead to the dehydration of epithelial surfaces, 
as excess sodium and water are reabsorbed into the cells. 
This dehydration of epithelial surfaces is in turn exacer-
bated by a loss of chloride, preventing the epithelium 
from rebalancing the low epithelial surface water volume. 
This mechanism manifests clinically as a build-up of pu-
rulent, thick mucus plugs which obstruct the airway  [14–
16] . With continuing pulmonary obstruction and infec-
tion, structural lung damage such as bronchiectasis oc-
curs, and there is a progressive loss of small airways 
function. This continuous vicious cycle begins in early 
childhood and continues through adolescence until death 
in adulthood  [17] .
 Individuals with CF are born with histologically nor-
mal lungs, however it has been shown that inflammatory 
processes are present in the lungs of children as young as 
4 weeks old, who are clinically free from infection  [18] . 
Chronic dysregulation of the innate host inflammatory 
response has been proposed as central to the CFTR defect. 
Ex vivo experimental studies have shown an increased 
baseline level of pro-inflammatory mediators and cyto-
kines in bronchoalveolar lavage samples of CF patients, 
further supporting this hypothesis  [3, 19] . Epithelial cell 
surface receptors recognize and respond to endogenous 
and exogenous pathogens via the activation of transcrip-
tion factors such as the nuclear factor κB (NF-κB) path-
way, which is responsible for the production of pro-in-
flammatory mediators  [1, 3] .
 Almost half of CF patients experience at least 1 pulmo-
nary exacerbation every 6 months, and patients with over 
2 exacerbations per year have an increased risk of a 5% 
decline in predicted FEV 1 % values  [20] . The most com-
mon pathogens which affect CF patients are bacterial in 
nature:  Pseudomonas aeruginosa ,  Staphylococcus aureus 
and methylpenicillin-resistant S. aureus (MRSA). Up to 
one third of children are chronically infected with  P. ae-
ruginosa by age 3, whilst 80% of patients will be chroni-
cally infected with the pathogen by age 25  [21] .  S. aureus 
 colonizes up to 67% of patients aged 6–17, whilst MRSA 
is consistently distributed across age groups, with a prev-
alence of 25.7%  [22] . Bacteria such as  Stenotrophomonas 
maltophilia and  Burkholderia cepacia  are less common in 
patients with standard infection rates of 13.7 and 2.5%, 
respectively; however, they are also associated with sig-
nificant reductions in FEV 1 % values and, in some acute 
infectious exacerbations, with early mortality  [3, 22] . 
Chronic  P. aeruginosa  infection in particular is associated 
with increased disease severity and a poorer prognostic 
outcome, and therefore the mechanism by which the in-
nate immune system and host inflammatory response is 
dysregulated is an area of significant interest to clinicians 
and scientists alike  [23–25] .
 This review is focused specifically on the mechanism 
of NF-κB-driven lung inflammation in CF and on the 
identification and role of cytoplasmic protein A20 as a 
negative regulator of this cascade. It includes novel thera-
peutic approaches with the potential to reduce chronic 
airway inflammation in CF by focusing on this central 
mechanism.
 Innate Immunity in CF 
 The ability to respond to pathogens is critical for health 
and survival. Pathogens are identified by pattern recogni-
tion molecules, namely the toll-like receptors (TLRs) on 
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epithelial and immune cells  [1] . In CF, activation of TLR-
2, TLR-3 or TLR-4 triggers an acute innate immune re-
sponse that is largely mediated by the transcription factor 
NF-κB to target gene expression and mediate the expres-
sion of inflammatory cytokines  [26] . Several studies  [27–
29] have shown altered TLR-4 expression in CF airway 
epithelial cells, which contributes to an increased inflam-
matory and deranged immune response.
 In a normal healthy host, TLR-4 is a pattern recogni-
tion molecule that specifically binds to the outer core oli-
gosaccharide of lipopolysaccharide (LPS), initiating an 
internalized response and signalling airway epithelial ac-
tivation  [30] . This immune response is rapid and self-lim-
iting and involves neutrophil recruitment, regulation of 
apoptosis and maintenance of airway epithelial integrity. 
In patients with CF, this instead leads to a prolonged ac-
tivation of the inflammatory response, as the CFTR air-
way and lung epithelial cells are unable to endocytose LPS 
and initiate a regulated NF-κB response  [30, 31] .
 In addition, increases in the cell membrane expression 
of compounds such as asialo-GM1 enable an increased 
attachment of both  P. aeruginosa  and  S. aureus  to the air-
way epithelium, without the initiation of the normal 
CFTR-mediated immune response  [32, 33] . The muco-
purulent environment of the CF airway acts as a reservoir 
for bacteria and infection, which leads to a prolonged and 
ineffective immune-mediated response, anecdotally re-
ferred to as the vicious cycle of CF. TLR-4 activation leads 
to NF-κB  activation and to subsequent translation of NF-
κB-driven target genes such as IL-8.
 In vitro Methods to Study Airways Inflammation
in CF 
 The epithelial cells lining the respiratory tract are the 
first point of contact between the outside world (bacteria, 
viruses, dust etc.) and the body. Initially, it was thought 
that these cells had a mere barrier function with the cilia 
pushing the foreign agents and mucus up to the mouth to 
be expectorated or swallowed. However, it is now recog-
nized that these cells are key players in the innate immune 
response and can secrete a host of inflammatory media-
tors, chemotactic agents and antimicrobial substances. 
Several approaches have been adopted to study these cells 
in the laboratory. There are a number of immortalized 
epithelial cell lines with and without mutations in CFTR 
available  [34] . In order to study primary epithelial cells, a 
number of investigators have isolated these cells from hu-
man lungs  [35] and nasal polyps  [36] . Although excellent 
sources for cells, both approaches suffer from some dis-
advantages. Human lungs from patients with CF are only 
obtained from those with end-stage disease who are un-
dergoing transplantation. Thus, it is difficult to obtain 
cells from patients with milder mutations and impossible 
to do longitudinal studies. For nasal polyps, access to sur-
gically resected material is required, and, again, longitu-
dinal studies are not possible. We therefore developed a 
method to isolate and grow primary epithelial cells using 
nasal brushings from patients with CF  [37] . These cells 
can be obtained from patients with different mutations 
and can be utilized for mediator release studies as well as 
for the investigation of the ion channel function  [38] . The 
procedure is minimally invasive and is well tolerated by 
patients and healthy volunteers. It can therefore be used 
to study epithelial cells from patients with milder muta-
tions as well as to follow longitudinal changes in epithe-
lial cell function.
 Sustained NF-κB-Mediated Inflammation Is a 
Hallmark of CF 
 NF-κB is a protein complex that controls the tran-
scription of DNA. Found in almost all human cell types, 
its activation is central to the innate immune response. In 
ensuring a timely termination of inflammation, NF-κB is 
tightly regulated. In individuals with underlying airways 
disease such as CF, this regulation is compromised, lead-
ing to sustained NF-κB activation and heightened chron-
ic inflammation, with further decreasing lung function 
 [39] .
 Under normal conditions, NF-κB is inactive, bound by 
a complex of inhibitory proteins such as IκBα. Stimula-
tion of the epithelial TLRs or TNF receptors by both ex-
ogenous and endogenous pathogens leads to the induc-
tion of a series of signalling cascades and the subsequent 
degradation of the IκB complex, which leads to the release 
of NF-κB  [40] . NF-κB consequently translocates to the 
nucleus and activates pro-inflammatory genes, such as 
p50 and p65, as depicted in  figure 1 , which maintain this 
state of inflammation through the release of inflamma-
tory cytokines. Within this receptor-ligand complex, a se-
ries of signal transduction pathways are activated before 
the translocation of p50 and p65 to the nucleus; most no-
tably these are the MyD88 and TRAF subunit 2 and 6 
proteins, which are ubiquinated receptor molecules with-
in this cascade  [41, 42] .
 Increases in pro-inflammatory mediators such as IL-6, 
IL-8, TNF-α and arachidonic acid metabolites have been 
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observed in CF patients  [39, 43, 44] . Concurrently, con-
centrations of anti-inflammatory substances such as IL-
10 and lipoxin are reduced, favouring a state of unabated 
inflammation  [45, 46] . 
 Maintaining cellular homeostasis is important for 
cells. Autophagy is a lysosomal process that induces the 
degradation of cytoplasmic constituents such as pro-
teins, lipids and organelles  [47] . Thereby, autophagy is 
a pivotal regulator of physiological processes such as de-
velopment, cell survival, differentiation and senescence, 
as reviewed earlier  [48] , as well as regulating inflamma-
tion and innate and adaptive immune responses  [49] , 
functions strongly regulated by NF-κB. On a molecular 
level, autophagy and NF-κB share common upstream 
signals and regulators and can control each other 
through positive or negative feedback loops, thus ensur-
ing homeostatic responses  [48] . In CF, the process of 
autophagy is defective, leading to an accumulation of 
misfolded or defective proteins such as CFTR, which has 
been described to drive autophagy inhibition  [50] . Fur-
thermore, autophagy is involved in the formation of ly-
sosomes and through a distinct phenomenon called 
LC3-associated phagocytosis facilitates the processing 
of TRL-4 phagosomes, for example  [51] . Interestingly, 
it has been shown that CF epithelial cells preferentially 
utilize recycling rather than lysosomal degradation 
upon LPS stimulation, which may be due to the inhib-
ited autophagy in CF cells  [26] . Rescuing autophagy 
may therefore interrupt the vicious cycle linking defec-
tive CFTR and lung inflammation  [50, 51] , and the stim-
ulation of autophagy (e.g. by rapamycin) has been 
shown to suppress lung inflammation in a model of CF 
 [52] . Considering the important role of NF-κB in the 
process of autophagy, the inhibition of NF-κB may be 
associated with reduced autophagy. Therefore, the goal 
of our research is not to inhibit NF-κB expression and 
activation, but to normalize it to a level observed in non-
CF cells.
 A20 Is a Central Negative Regulator of NF-κB 
 A20 (TNFAIP-3) is a central and inducible regulator 
of NF-κB, regulating multiple signalling cascades. Basal 
expression in most cells is normally low; however, it is 
rapidly upregulated in response to previously described 
pathogenic stimuli, such as TNF-α and LPS  [53] . A20 
negatively regulates NF-κB driven pro-inflammatory sig-
nalling upon TLR activation at the level of the TRAF6 
activation  [42, 43] ( fig. 2 ).  Persistent NF-κB activation 
suggests that this tightly regulated signalling pathway is 
distorted in CF  [26, 31, 54] . The PubMed database was 
searched for (A20 or TNFAIP-3) and CF, and abstracts 
from the European Cystic Fibrosis Society conferences 
were examined. The patent database was searched for gib-
berellin (GA 3 ) derivatives.
 Fig. 1. Schematic outline showing the production of pro-inflam-
matory cytokines via TLR-4-mediated TRAF6 activation of NF-
κB and the translocation of p50 and p65 to the nucleus. IKKα = 
Inhibitor of NF-κB kinase subunit α; IKKβ = inhibitor of NF-κB 
kinase subunit β; IL-1R = interleukin-1 receptor; NEMO = NF-κB 
essential modulator; p50 = p50 subunit of NF-κB; p65 = p65 sub-
unit of NF-κB; TAB2 = transforming growth factor-β-activated 
kinase 1 binding protein 2; TAB3 = transforming growth factor-
β-activated kinase 1 binding protein 3; TAK = transforming 
growth factor-β-activated kinase; TNFR = tumour necrosis factor 
receptor; TRAF6 = TNF receptor-associated factor 6; ub = ubiq-
uitin. 
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 While the first innate response to pathogens is medi-
ated by pro-inflammatory NF-κB, the induction of A20 is 
described as the ‘anti-inflammatory arm’ of NF-κB sig-
nalling  [55] . The A20-TRAF6 axis is critical in preventing 
LPS-stimulated NF-κB activation: A20 silencing restores 
TRAF6 action and increases NF-κB activation following 
stimulation with LPS  [56] . Following TLR4 activation, 
A20 first inactivates TRAF6 by deubiquitination and dis-
ruption of the interaction with an ubiquitin ligase and 
then ubiquitinates TRAF6, which initiates proteasomal 
degradation  [41, 42] . 
 Inhibitory A20 action also depends on the A20 ubiq-
uitin-editing complex formed with RNF11, Itch (ligase) 
and TAX1BP1 (TRAF6-binding protein)  [57, 58] . This 
interaction is rapid and transient and governs A20 action 
by promoting TRAF6 deubiquitination and disrupting 
TRAF6 association with the ligase, thereby terminating 
the NF-κB activation  [41] . Similarly, in TNF receptor sig-
nalling, A20 removes the activating K63-polyubiquitin of 
the protein kinase RIP (RIPK1), then acts as a ligase, pro-
moting K48 polyubiquitination and degradation of 
RIPK1  [59] .
 However, a recent paper by De et al.  [60] has suggested 
that in mice the deubiquitinase activity of A20 is not 
needed for normal NF-κB signalling, suggesting that this 
role is taken over by a different deubiquitinase.
 A20: A Multidisease Model 
 A20, a zinc finger protein, was initially researched as a 
tumour suppressor gene  [61] , but has since been impli-
cated in various inflammatory diseases such as inflamma-
tory bowel disease, systemic lupus erythematosus, type 1 
diabetes, psoriasis, rheumatoid arthritis and multiple 
sclerosis, where it serves as a susceptibility gene/biomark-
er of disease development  [62] . In animal studies, mice 
lacking enterocyte A20 developed an overwhelming sys-
temic inflammation following treatment with TNF-α 
 [63] . A20 also inhibits NF-κB activation in bronchial ep-
ithelial cells following influenza infection  [64] , and en-
hanced A20 mRNA expression was observed in mice fol-
lowing the introduction of  P. aeruginosa  infection after a 
1-hour incubation period  [65] . 
 A20 in CF Airway Disease 
 In the lung, A20 is rapidly induced by  P. aeruginosa 
 and is essential for the termination of the TLR4-signalled 
release of IL-8 from primary airway epithelial cells  [66] . 
A20 prevents the translocation of p65 to the nucleus, thus 
mediating and downregulating the inflammatory re-
sponse. In keeping with this, it has been found that the 
silencing of A20 increases cellular levels of p65 and in-
duces a pro-inflammatory state  [67] . Transient increases 
in A20 following the stimulation of primary nasal epithe-
lial cells with LPS have been shown, but CF primary nasal 
epithelial cells express less A20 basally and following LPS 
stimulation, suggesting that A20 expression is related to 
CFTR functionality  [39] .
 In CF, the adapter protein TAX1BP1 within the 
ubiquitin-editing complex is shown to be significantly 
reduced in LPS-treated cells  [39, 40] . In this complex, 
A20 and TAX1BP1 directly interact to prevent TRAF6 
polyubiquitination and thus stop the TLR-mediated in-
flammatory signalling response. In the absence of 
TAX1BP1, A20 cannot bind to target proteins  [41, 57] . 
 Fig. 2. The role of the A20 ubiquitinating complex at the TRAF6 
level. Modified from Kelly et al.  [40] . 
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Kelly et al.  [68] explored the relationship of TAX1BP1 
and A20 and found that F508:F508del (homozygous)
epithelial cells expressed significantly less A20 than 
R117H/F508del (heterozygous), p < 0.05 ( fig. 3 a). As ex-
pected, NF-κB (p65) expression is increased in CF geno-
types compared to non-CF epithelial cells ( fig. 3 b). Inter-
estingly, Kelly et al.  [68] also reported TAXB1BP1 expres-
sion to be only reduced in F508del (homozygous) CF cells 
but not in those with a milder disease (R117H/F508del).
 A20 Expression Correlates with Lung Function in CF 
 A20 expression in both of the predominant CF geno-
types F508:F508del and R177H/F508del is inversely pro-
portional to p65 expression  [39, 68] , which has a direct 
correlation with NF-κB activity  [69] ( fig.  3 c). To date, 
these are the only mutations which have been examined 
with respect to A20 expression. Most importantly, Kelly 
et al.  [68] also observed a significant relationship between 
deteriorating FEV 1 % and basal A20 expression. Of par-
ticular note, those cases with the poorest lung function 
were also those with the most severe reduction in A20 
expression. 
 CF is a heterogeneous disease, and the phenotypic se-
verity of the condition can be significantly varied; these 
findings suggest that the reduction of A20 in epithelial 
cells largely reflects the genotype and disease severity. The 
above findings suggest that A20 has the potential to be a 
predictor of both inflammation and disease severity in 
CF, which has merited further exploratory studies focus-
ing on the role of A20 and other, similar molecules as 
mediators of inflammation within CF. 
 Induction of A20 by GA 3 Is Anti-Inflammatory 
 GA 3 hormones are naturally occurring plant diter-
penes biosynthesized from ent-kaurenes implicated in 
plant growth  [70] . Several diterpenoids possess strong 
anti-inflammatory properties. Most notably, forskolin 
can reduce inflammation in asthma and histamine release 
through cAMP-dependent mechanisms; however, for-
skolin is independent of the mechanisms discussed in this 
context  [71] . GA 3 has been shown to have anti-inflamma-
tory properties in diabetic mice  [72] . Patents exist to de-
velop GA 3 formulations for the treatment of diabetes and 
its complications  [73] , prostatitis and psoriasis  [74] , 
thereby highlighting the increasing interest in developing 
GA 3 for preclinical and clinical trials. 
a
b
c
 Fig. 3. Role of A20 in CF.  a ,  b Kruskal-Wallis one-way ANOVA
(n = 6–10). A20 expression ( a ) and p65 expression ( b ) are related 
to the CF genotype.  c A20 expression correlates negatively with 
NF-κB (p65) expression. Modified from Kelly et al.  [39, 68] . 
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 As a proof of principle, our preliminary data have con-
firmed that GA 3 pretreatment significantly induced A20 
in LPS-stimulated bronchial epithelial cells, which was 
associated with a significant reduction in LPS-induced 
IL-8 release ( fig. 4 ). Therefore, we hypothesize that phar-
macological induction of A20 could be a potential new 
treatment for persistent inflammation in CF  [75] . 
 Modification of A20: Anti-Inflammatory Immune 
Response-Enhancing Therapy 
 Given its role in modulating innate immunity and NF-
κB activation, the pharmacological induction of A20 can 
be predicted to be anti-inflammatory. In mice, the viral 
transfer of A20 attenuates ovalbumin-induced allergic 
asthma, inhibits mucus production and cytokine release 
and prevents airway hyperresponsiveness  [76] . Probiotics 
facilitate their anti-inflammatory action through the in-
duction of A20, and it has been shown that A20 induction 
by modified  P. aeruginosa attenuates allergic airway in-
flammation in mice and human bronchial epithelial cells 
 [77] .
 Advances in CF treatment will see an aging CF popula-
tion in the future. Despite recent advances in CFTR mod-
ulatory therapies, there is a need to introduce new first-
in-class (different mechanism of action than already ap-
proved medicines) anti-inflammatory drugs that can 
normalize the inflammatory response and help to con-
tribute to healthier aging in patients with CF.
 The development of new first-in-class medicines costs 
approximately USD 1.2 billion for a single approved drug 
 [78, 79] and can take up to 10–15 years to develop  [80, 
81] . Many of these drugs perform well in the preclinical 
testing but fail when tested in humans. The failure to 
translate drug candidates from animal models to humans 
has led to questions about the utility of in vivo studies  [82, 
83] . Alternative approaches and more predictive models 
of drug research are identified areas of interest for drug 
research and development.
 Drug Repositioning, Connectivity Mapping and 
Making New Drugs from Old 
 Drug repositioning offers an exciting opportunity to 
utilize and repurpose existing, licensed treatments, with 
the major benefit of providing a far more rapid route to 
clinic than by novel drug discovery approaches, removing 
the need for many animal experiments, particularly toxi-
cology, efficacy and dose-tolerance studies. There are two 
main approaches to drug repositioning: firstly, to investi-
gate drugs within the mechanism of action for which they 
are already licensed, for example the repositioning of 
sildenafil by Pfizer for use in erectile dysfunction  [84] . 
The more innovative approach, known as gene expres-
sion connectivity mapping, aims to identify novel targets 
for existing drugs. Gene mapping is an advanced bio-in-
formatics technique to establish the connections among 
different biological states via their gene expression pro-
files/signatures. One major application of connectivity 
mapping is to identify potential small molecule com-
pounds able to inhibit a disease state or regulate the ex-
pression of a small number of genes  [85, 86] . This has 
been successfully applied to phenotypic targeting in a dif-
ferent setting: entinostat was predicted and subsequently 
validated as an effective inhibitor of the disease pheno-
type in acute myeloid leukaemia  [87] .
 Together we performed a compound search using 
gene expression connectivity mapping to identify existing 
drugs that could induce A20 expression  [88] . A total of 53 
individual gene array sample sets of airway epithelial cells 
from patients with and without CF from 6 independent 
public datasets were used.
 Within the process of gene expression connectivity 
mapping, genes associated in their mRNA expression to 
that of A20 were determined. The so-called A20-associ-
ated genes together with the seed gene A20 form the gene 
signature, a short list of important genes, selected from 
Co
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 Fig. 4. Effect of GA 3 pretreatment on LPS-induced IL-8 release 
from control (HBE) and CF (CFBE) epithelial cells.  *   p < 0.0,
 * * *  p < 0.001 (one-way ANOVA). 
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the gene array data through regression analysis. The 
genes identified in CF were activating transcription factor 
3, intercellular adhesion molecule-1, a member of the 
RAS oncogene family (RAB5C) and domain-containing 
protein (DENND4A). Quantitative RT-PCR analyses in 
CF and non-CF cell lines confirmed a reduced basal ex-
pression and a lower LPS-induced expression of these 
genes, similar to A20 in these genes  [39, 88] . Together 
with A20, these A20 associates then served as an input to 
the connectivity mapping process (www.broadinstitute.
org) to predict small molecules already licensed for the 
use in humans that will enhance A20 expression. Cur-
rently, we are testing these molecules to check that they 
act as A20 inducers and have anti-inflammatory effects 
on our isolated epithelial cell preparations. 
 Conclusion 
 A20 is crucial in regulating the innate NF-κB-driven 
response to infections. As A20 expression in airway epi-
thelial cells from patients with CF is reduced, it remains 
a potential therapeutic target to normalize inflammation; 
however, a drug to increase A20 expression is not cur-
rently available. Data using GA 3 strongly suggest that the 
pharmaceutical induction of A20 reduces NF-κB-driven 
inflammation in airway epithelial cells. Our current work 
has found genes which behave like A20, and, using con-
nectivity mapping, we are predicting several drugs al-
ready licensed for use in humans that are potentially ca-
pable of inducing A20. This approach, if successful, will 
take our work on isolated cells truly from bench to bed-
side. 
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